San Francisco, United States
AusperBio Therapeutics, Inc.
$120.0M
Series C
Summary
AusperBio Therapeutics, Inc. completed a $120 million Series C financing. The company said the financing will support advancement of AHB-137 toward potential commercialization and accelerate development of AHB-171 and next-generation combination approaches for chronic hepatitis B. AusperBio Therapeutics, Inc. is a near-commercial biopharmaceutical company.
Investors
new and existing investors, RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, CDH Investments, a leading strategic investor, RA Capital Management, L.P.